Photodynamic Therapy with Bilirubin-Coated Nanoparticles

Back to all technologies
Download as PDF
2019-WON-68496
Researchers at Purdue University have developed nanoparticles for use in photodynamic therapy that are activated by x-rays and can target tumors in deeper tissue. Photodynamic therapy currently uses photosensitizing agents to directly kill cancer cells and is used in combination with radiation therapy to enhance its anti-tumor effects. However, the therapy is limited to skin tumors because it requires photosensitizing agents that are activated by light in the UV-visible range, which can only pass through ~1/3 of an inch. Unlike other competing nanoparticle enhancers which require administration of systemic photosensitizing agents, these nanoparticles are coated with bilirubin which acts as the photosensitizer. The nanoparticles demonstrated a 1.4 fold improvement over x-rays alone in killing cancer cells in a cell survival assay. Applications for this technology are in the treatment of cancer.

Advantages:
-Localized delivery of therapy
-1.4 fold improvement in killing cancer cells in vitro
-Low toxicity

Potential Applications:
-Photodynamic therapy
-Cancer treatment
Jan 10, 2020
PCT-Patent
WO
(None)
(None)

Jan 22, 2019
Provisional-Patent
United States
(None)
(None)

(None)
NATL-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org